About the Authors
- Hiroyuki Ito
-
Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Visualization, Writing – original draft
* E-mail: ito@edogawa.or.jp
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Suzuko Matsumoto
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Takuma Izutsu
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Eiji Kusano
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Jiro Kondo
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Hideyuki Inoue
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Shinichi Antoku
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Tomoko Yamasaki
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Toshiko Mori
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
- Michiko Togane
-
Roles Investigation, Writing – review & editing
Affiliation Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, Edogawa, Tokyo, Japan
Competing Interests
H Ito has received funding support and lecture fees from Taisho Pharmaceutical Co., Ltd., and lecture fees from Eli Lilly Japan KK, Boehringer Ingelheim, Takeda Pharmaceutical Company Ltd., Sanofi KK, Novo Nordisk Pharma Ltd., MSD KK, Novartis Pharma KK, Astellas Pharma, Daiichi Sankyo Company, Terumo Corporation, Mochida Pharmaceuticals, Teijin Pharma, Kissei Pharmaceuticals, Kowa Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Sanwa Kagaku Kenkyusho, Dainippon Sumitomo Pharma, AstraZeneca KK, Kyowa Hakko Kirin, Shionogi and Co, Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd., and has received consulting fee from Becton, Dickinson and Company. S Matsumoto has received lecture fees from Novo Nordisk Pharma Ltd., Astellas Pharma, and AstraZeneca KK. T Izutsu has received lecture fees from Sanofi KK, Taisho Pharmaceutical Co., Ltd., Kyowa Hakko Kirin, Bayer Yakuhin, Ltd., and Mitsubishi Tanabe Pharma Corporation. S Antoku has received lecture fees from Kyowa Hakko Kirin, Sanofi KK, Kyowa Hakko Kirin, Taisho Pharmaceutical Co., Ltd., Daiichi Sankyo Company, and Otsuka Pharmaceutical Co., Ltd. E Kusano, J Kondo, H Inoue, T Yamasaki, T Mori and M Togane have no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.